Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus JENTADUETO XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus JENTADUETO XR.
JANUVIA vs JENTADUETO XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
100 mg orally once daily
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Category C
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor / Biguanide Combination